Clinically, our study underscores the utility of advanced molecular profiling and patient-specific controls in refining diagnostics, aligning with evolving guidelines for myeloid malignancy management and highlights the need for further studies to clarify TRIB1's role in MDS pathogenesis. The gene discussed is TRIB1; the disease is myelodysplastic syndrome.